Beijing Konruns Pharmaceutical News

Kangchen Pharmaceutical (603590): Sales model changes affect short-term performance, innovative drug development continues to advance

CITIC SecuritiesDec 2 00:00

Kangchen Pharmaceutical (603590): Sales of core products have fluctuated, and innovative drug research and development is progressing steadily

Sep 6 00:00

Kangchen Pharmaceutical (603590): The clinical pipeline is progressing in an orderly manner under pressure on performance

Sep 2 14:51

Kangchen Pharmaceutical (603590): KC1036Phase III continues to promote Jincao tablets and will soon be declared for listing

Aug 28 00:00

Kangchen Pharmaceutical (603590): ZY5301 clinical results published in the JAMA journal, optimistic about subsequent R&D progress

Jul 30 00:00

Kangchen Pharmaceutical (603590) Company Brief Review Report: Rapid growth of core products and continuous breakthroughs in innovative drug research and development

May 21 00:00

Kangchen Pharmaceutical (603590): Steady release of core products and the R&D pipeline is progressing smoothly

May 11 19:26

Deep* Company* Kangchen Pharmaceutical (603590): Strong profit side performance, successful implementation of innovative achievements

Apr 29 18:31

Kangchen Pharmaceutical (603590): The R&D project for continuous release of core products is progressing smoothly

Apr 29 00:00

Kangchen Pharmaceutical (603590): Suling boosts performance growth, key innovative drug pipelines are progressing smoothly

Apr 26 00:00

Deep* Company* Kangchen Pharmaceutical (603590): Strong profit side growth, multi-project R&D pipeline progressing smoothly

Apr 11 11:01

Bank of China Securities released a research report on April 11 stating that Kangchen Pharmaceutical (603590.SH) was given a purchase rating. The main reasons for the rating include: 1) the profit-side growth rate is impressive, and “Su Ling” continues to

Zhitong FinanceApr 11 10:37

Kangchen Pharmaceutical (603590): Gradual harvesting of Jincao tablets in the research pipeline is expected to fill gaps in treatment

Mar 21 00:00

Kangchen Pharmaceutical (603590): KC1036 clinical research is progressing and commercialization prospects are promising

Dec 26, 2023 00:00

Kangchen Pharmaceutical (603590): KC1036 clinical phase III is about to begin, and is expected to provide new options for ESCC afterline medication

Nov 29, 2023 18:56

Kangchen Pharmaceutical (603590): R&D ushered in a breakthrough, KC1036 approved for phase III clinical study

Nov 29, 2023 00:00

Kangchen Pharmaceutical (603590) Company Brief Review Report: Profit Side Performance Exceeds Expectations, Waiting for Breakthroughs in Innovative Drug Development

Nov 13, 2023 20:12

Kangchen Pharmaceutical (603590): Q3 Su Ling continued to release KC1036, and more clinical trials progressed steadily

Nov 1, 2023 00:00

Kangchen Pharmaceutical (603590): 2023Q3 revenue increased steadily year-on-year, and increased gross margin led to impressive performance on the profit side

Oct 31, 2023 00:00

Kangchen Pharmaceutical (603590): Su Ling accelerates the volume release R&D pipeline and actively promotes

Oct 30, 2023 19:56